布地奈德、硫酸特布他林、异丙托溴铵气雾剂联合雾化吸入治疗小儿喘息性支气管炎的效果观察简

目的观察临床联合运用布地奈德、硫酸特布他林、异丙托溴铵气雾剂吸入治疗小儿喘息性支气管炎的效果及安全性。方法选择喘息性支气管炎患儿216例，随机分为观察组108例，对照组108例，两组均使用相同的抗感染、止咳平喘、吸氧等治疗。观察组加吸入用布地奈德混悬液、硫酸特布他林雾化液、异丙托溴铵气雾剂联合雾化吸人。对照组则使用地塞米松、α-糜蛋白酶雾化吸人。对两组的症状及体征得到明显改善的时间、总有效率及不良反应发生率进行比较。结果观察组在临床症状咳嗽以及喘息上明显改善的时间及肺部体征消失时间均较对照组短，差异有统计学意义f咳嗽：（4．32±1．41）d比（7．81±1．20）d，t=10．547，P=0．007；喘息：（3．15±0．92）d比（5．23±1．21）d，t=9．973，P=0．008；肺部体征：（3．47±1．12）d比（7．05±1．31）d，t=10．182，P=0．008]；观察组总有效率为95．4％．对照组为78．7％，两组比较，差异有统计学意义（X2=13．295，P=0．000）；观察组不良反应发生率为1．85％，对照组为2．78％，差异无统计学意义（X^2=0．030，P=0．978）。结论联合运用布地奈德、硫酸特布他林、异丙托溴铵气雾剂经压力雾化泵吸入治疗小儿喘息性支气管炎效果显著，且无明显不良反应，值得临床推广应用。

Observation on curative effect and safety of combined therapy of Budes- onide,Terbutaline Sulphate and Ipratropium Bromide for children with asthmatic bronchitis

Objective To observe the effects and safety of combined therapy of Budesonide, Terbutaline Sulphate and Ipratropium Bromide for children with asthmatic bronchitis. Methods 216 children with asthmatic bronchitis were ran- domly divided into the observation group （n=108） and the control group （n=108）. Both groups were used with the same treatment of anti-infection, relieving cough and asthma, oxygen, etc. The observation group was treated with Budes- onide, Terbutaline Sulphate and Ipratropium Bromide. The control group was treated with Dexamethasone and c±-ehy- motrypsin. The time of symptoms and signs of significant improvement, the total efficiency and the incidence of adverse reactions were compared. Results The clinical symptoms of cough and asthma and the pulmonary signs disappearance time of the observation group were shorter than the control group, the differences were statistically significant [cough： （4.32±1.41） d vs （7.81±1.20） d, t=10.547, P=0.007; asthma： （3.15±0.92） d vs （5.23±1.21） d, t=9.973, P=0.008; the pulmonary signs： （3.47±1.12） d vs （7.05±1.31） d, t = 10.182, P = 0.008]. The total effective rate of the observation group was 95.4%, and the control group was 78.7%, the difference was statistically significant （X2=13.295, P=0.000）. The ad- verse reaction rates of the two groups were 1.85% and 2.78%, there was no statistically significant difference between the two groups （X2=0.030, P=0.978）. Conclusion The combined therapy of Budesonide, Terbutaline Sulphate and Iprat- ropium Bromide is effective for children with asthmatic bronchitis and has no side effect, which is worthy of clinical ap- plication.